Literature DB >> 21855286

Heparin-induced thrombocytopenia type II in a surgical intensive care unit.

Yasser Sakr1, Friederike Haetscher, Mateus Demarchi Gonsalves, Michael Hoffman, Bernhard Theis, Dagmar Barz, Konrad Reinhart, Andreas Kortgen.   

Abstract

PURPOSE: The aim of this study was to investigate the epidemiology of and outcome from heparin-induced thrombocytopenia type II (HIT) in surgical intensive care unit (ICU) patients. PATIENTS AND METHODS: All 13,948 patients admitted to a university hospital surgical ICU between January 2004 and March 2008 were included in this retrospective cohort study.
RESULTS: Of 349 patients with a clinical suspicion of HIT, 88 patients had platelet factor 4/heparin antibodies using enzyme-linked immunosorbent assay. The prevalence and incidence of HIT were 0.82% and 0.63%, respectively. The complication rate was 43.5%, and the ICU and hospital mortality rates were 23.9% and 33%, respectively. In a multivariable analysis, the nadir platelet count (odds ratio, 1.03; 95% confidence interval, 1.01-1.05; P = .048) was the only factor independently associated with risk of death in these patients. In a nested matched case-control analysis, mortality rates were similar in patients with HIT and in the matched controls. However, complication rates were higher, and ICU and hospital lengths of stay were longer in patients with HIT compared with those of the control group.
CONCLUSIONS: In this cohort of surgical ICU patients, HIT was associated with increased morbidity but not mortality rates compared with a nested matched control group. The nadir platelet count was independently associated with a higher risk of in hospital death in these patients.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21855286     DOI: 10.1016/j.jcrc.2011.06.016

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  4 in total

Review 1.  Molecular and cellular pathogenesis of heparin-induced thrombocytopenia (HIT).

Authors:  Lubica Rauova; Gowthami Arepally; Mortimer Poncz; Douglas B Cines
Journal:  Autoimmun Rev       Date:  2018-08-10       Impact factor: 9.754

2.  Anticoagulation strategies in venovenous hemodialysis in critically ill patients: a five-year evaluation in a surgical intensive care unit.

Authors:  Christoph Sponholz; Ole Bayer; Björn Kabisch; Karin Wurm; Katharina Ebert; Michael Bauer; Andreas Kortgen
Journal:  ScientificWorldJournal       Date:  2014-12-09

3.  Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial.

Authors:  Brigitte Tardy-Poncet; Philippe Nguyen; Jean-Claude Thiranos; Pierre-Emmanuel Morange; Christine Biron-Andréani; Yves Gruel; Jérome Morel; Alain Wynckel; Lelia Grunebaum; Judith Villacorta-Torres; Sandrine Grosjean; Emmanuel de Maistre
Journal:  Crit Care       Date:  2015-11-11       Impact factor: 9.097

4.  Heparin-Induced Thrombocytopenia in a Patient with Essential Thrombocythemia: A Case Based Update.

Authors:  Edva Noel; Naeem Abbas; Yevegeniy Skaradinskiy; Zwi Schreiber
Journal:  Case Rep Hematol       Date:  2015-10-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.